Mix Sector Stock In Focus: Twitter, Inc. (NYSE:TWTR), West Pharmaceutical Services, Inc. (NYSE:WST), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Twitter, Inc. (NYSE:TWTR) surged over 2.6% in previous trading session following a fake story appeared on a faux website with the intention of asserted that Twitter had received a conquest offer. It ran on a site that was a close facsimile of the one run by Bloomberg LP, mimicking Bloomberg’s style and layout and even using a Bloomberg reporter’s name in the byline. A search of the WhoIs domain registry shows the site was registered four days ago, on July 10. A spokesperson for Bloomberg confirmed that the story was fake. A Twitter spokesperson declined to comment. Twitter’s stock had been up in earlier trading, but then spiked in the minutes after 11:36 a.m. New York time, the time stamp on the fake story. The article falsely claimed that “Twitter is working closely with bankers after receiving an offer to be bought out for $31 billion, people with knowledge of the situation said.” Twitter, Inc. (NYSE:TWTR) stock hit highest price at $38.82, beginning with a price of $35.78 to the closed at 36.72 by a gain of 2.63% with a day range of $35.77-$38.82.

West Pharmaceutical Services, Inc. (NYSE:WST) reported on Tuesday that its BOD has permitted a Q4 2015 dividend of $0.12 per share, a 9.1% increase over the $0.11 per share declared for each of the four preceding quarters. This is the twenty-third consecutive annual increase in the company’s dividend. The fourth quarter dividend will be paid on November 4 to shareholders of record as of October 21. On the other consideration, West Pharmaceutical Services, Inc. (NYSE:WST) begun last trade with a price of $60.38 and throughout the trading session climbed at $61.00. The day-trade ended with an advance of 0.73% to close at $60.82. The stock is going forward its fifty-two week low with 56.54% and lagging behind from its 52 week high price with -0.78%. WST last month stock price volatility remained 1.86%.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released that it has commenced an underwritten public offering of around $250M of its common shares. The firm also reported that it anticipates to grant the underwriters of the offering an option for a quarter of 30 days to purchase up to an additional $37.5M shares. Ultragenyx declared that it intends to use the net proceeds of the offering to accelerate commercial launch preparation for Ace-ER, rhGUS, and KRN23 in the U.S. and other markets. The company may also use a portion of the net proceeds to in-license, acquire, or invest in additional businesses and technologies. It may use any remaining proceeds to invest in early-stage translational research, additional clinical activities, and general corporate purposes. Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at $119.31 with 35.90 million outstanding shares and hit to its highest price of $127.55 during the day and finally closed at $126.77 by scoring 6.56%.